CA-C3.AI
Shell (NYSE:RDS), C3 AI (NYSE:AI), Baker Hughes (NYSE:BKR), and Microsoft (NASDAQ:MSFT) today announced the launch of the Open AI Energy Initiative™ (OAI), a first-of-its-kind open ecosystem of artificial intelligence (AI)-based solutions for the energy and process industries. The OAI provides a framework for energy operators, service providers, equipment providers, and independent software vendors for energy services to offer interoperable solutions, including AI and physics-based models, monitoring, diagnostics, prescriptive actions, and services, powered by the BHC3™ AI Suite and Microsoft Azure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210201005936/en/
“This initiative is about combining the efforts of global leaders to accelerate the digital transformation of the energy industry to new, safe, and secure energy and to ensure climate security,” said C3 AI CEO Thomas M. Siebel.
The first set of OAI solutions provided by Shell and Baker Hughes are focused on reliability and designed to improve uptime and performance of energy assets and processes. These reliability solutions will serve as extensions to the current BHC3 Reliability application, an AI-based application that provides reliability, process, and maintenance engineers with AI-enabled insights to predict process and equipment performance risks for the energy industry. The application leverages the BHC3 AI Suite’s ability to integrate enterprise-scale data from disparate data sources and train AI reliability models that cover full plant operations while taking full advantage of Azure, Microsoft’s scalable, enterprise-class cloud infrastructure.
The OAI augments BHC3 Applications with partner-led, domain-specific solutions that accelerate deployment of AI-based reliability solutions to unlock significant economic value across the energy industry while helping to make energy production cleaner, safer, and more efficient. The initial OAI reliability solutions offered by Shell and Baker Hughes enable interoperability between BHC3 Reliability, OAI modules, and existing industry solutions for such applications. Solutions available today include proven and tested equipment- and process-specific modules with pre-trained AI models, codified subject matter expertise, low-latency data connectors, thermodynamic and operating parameter libraries, global health monitoring services, deep diagnostics, failure prevention recommendations, and prescriptive actions.
Shell is making modules available through the OAI, including:
- Shell Predictive Maintenance for Control Valves
- Shell Predictive Maintenance for Rotating Equipment
- Shell Predictive Maintenance for Subsea Electrical Submersible Pumps
Baker Hughes will offer OAI interoperability with a range of existing technologies in the energy industry, including:
- iCenter – Turbomachinery Advanced Digital Services
- Bently Nevada System 1 Condition Monitoring Software
- Baker Hughes Valve Lifecycle Management
The Open AI Energy Initiative will augment Baker Hughes and C3 AI Applications, including:
- BHC3 Reliability
- BHC3 Production Optimization
- BHC3 Inventory Optimization
- C3 AI CRM
“Digital technologies and AI are helping us improve our core business today and build the energy businesses of the future. Over the last few years, we have been working with C3 AI to scale our AI-based predictive maintenance solutions to reduce costs and improve the productivity, reliability, and performance of our assets,” said Shell Chief Technology Officer Yuri Sebregts. “We are monitoring more than 5,200 pieces of equipment using machine learning across upstream and downstream manufacturing as well as integrated gas assets. We are excited to take this capability to market and want to develop an open ecosystem where others can offer AI solutions to help improve reliability across the industry.”
“Taking energy forward requires new approaches to technology that leverage collaboration, open data standards, and cutting-edge AI capabilities,” said Uwem Ukpong, executive vice president of regions, alliances & enterprise sales at Baker Hughes. “Working alongside our alliance partners at C3 AI and together with industry leaders at Shell and Microsoft, the OAI will help address the persistent industry challenge of nonproductive downtime. This new ecosystem will leverage our strong existing BHC3 portfolio and is a promising step in the digital transformation of energy.”
“ Microsoft is committed to the transformation of the energy sector and supporting solutions like the Open AI Energy Initiative, which are contributing to the realization of these transformation goals,” said Microsoft Vice President of Energy Darryl Willis. “Digital technology is helping key industry areas such as plant reliability and maintenance, and Microsoft’s participation in the Open AI Energy Initiative will further advance the transition to a net-zero emissions future.”
“The Open AI Energy Initiative is an early but clear reflection of the direction the market is heading,” said Kevin Prouty, IDC group vice president, energy and manufacturing insights. “With this already-established alliance of leading organizations, including C3 AI, Shell, Baker Hughes, and Microsoft, the OAI is poised to single-handedly establish the ecosystem of enterprise AI for the energy industry.”
Learn more about the Open AI Energy Initiative and its reliability solutions at https://bakerhughesc3.ai/products/bhc3-oai/
About C3.ai, Inc.
C3.ai, Inc. (NYSE:AI) is a leading provider of enterprise AI software for accelerating digital transformation. C3 AI delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai
About Royal Dutch Shell plc
Royal Dutch Shell plc is incorporated in England and Wales‚ has its headquarters in The Hague and is listed on the London‚ Amsterdam‚ and New York stock exchanges. Shell companies have operations in more than 70 countries and territories with businesses including oil and gas exploration and production; production and marketing of liquefied natural gas and gas to liquids; manufacturing‚ marketing and shipping of oil products and chemicals and renewable energy projects. For further information‚ visit www.shell.com .
About Baker Hughes
Baker Hughes (NYSE: BKR) is an energy technology company that provides solutions to energy and industrial customers worldwide. Built on a century of experience and with operations in over 120 countries, our innovative technologies and services are taking energy forward – making it safer, cleaner and more efficient for people and the planet. Visit us at bakerhughes.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005936/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom